Biotech startups in the United Kingdom
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| bit.bio | Cambridge | Series D | $25.0M | 2026-11-04 |
| T-Therapeutics | Cambridge | Series B | $133.0M | 2026-11-05 |
| Basecamp Research | London | Series C | $140.0M | 2026-09-23 |
| Brainomix | Oxford | Series C | $6.5M | 2026-02-24 |
| Microbiotica | Cambridge | Series C | $47.9M | 2026-10-16 |
| Bioliberty | Edinburgh | Series A | $3.3M | 2026-11-02 |
| Sparxell | Cambridge | Seed | $5.0M | 2026-02-03 |
| Alchemab Therapeutics | London | Series A | $33.6M | 2026-07-09 |
8 rows of the CSV in 5 of its 18 columns.
- The 638 biotech startups in the United Kingdom have raised $10.6B in total.
- 90 of them closed their most recent round in the last 12 months, $2.3B combined.
- The largest of those rounds is OMass Therapeutics' $310.0M Series C, dated October 2026.
- The most recent is T-Therapeutics' $133.0M Series B on 5 November 2026.
- Innovate UK is an investor in 30 of them, more than any other fund.
- Health care is the most common other sector, with 457 companies (72%).
- 37% were founded in 2020 or later; the median founding year is 2018.
- The most common team size is 1 to 10 employees (48% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 638| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| T-Therapeutics | T-Therapeutics develops T cell receptor therapies, spun off from the University of Cambridge. | Biotech | Cambridge | Series B | $133.0M | 2026-11-05 | $224.6M | F-Prime, Sofinnova Partners, Digitalis Ventures +2 | 51 to 100 | 2022 |
| bit.bio | Bit.bio provides engineered human cell products and platform services for biomedical research and drug discovery. | Biotech | Cambridge | Series D | $25.0M | 2026-11-04 | $250.0M | Metaplanet, Foresite Capital | 101 to 250 | 2016 |
| Bioliberty | Bioliberty develops rehabilitation solutions for degenerative and traumatic conditions as a medtech start-up. | Biotech | Edinburgh | Series A | $3.3M | 2026-11-02 | $17.4M | Innovate UK, Scottish Enterprise, Old College Capital +2 | 11 to 50 | 2020 |
| Microbiotica | Microbiotica develops live bacterial microbiome therapeutics and associated biomarkers. | Biotech | Cambridge | Series C | $47.9M | 2026-10-16 | $130.7M | Seventure Partners, IP Group, Cambridge Innovation Capital +1 | 11 to 50 | 2016 |
| Sava Technology | Sava Technology creates under-skin sensors that continuously monitor glucose, lactate, and ketones. | Biotech | London | Series B | $36.0M | 2026-10-09 | $62.8M | SOSV, Balderton Capital, Social Starts +1 | 101 to 250 | 2016 |
| Basecamp Research | Basecamp Research is a biotechnology company that uses AI and biological data to develop therapeutics. | Artificial intelligence | London | Series C | $140.0M | 2026-09-23 | $219.9M | True Ventures, redalpine, Hummingbird Ventures +1 | 51 to 100 | 2019 |
| Mironid | Mironid discovers drugs to treat degenerative kidney diseases, chronic inflammatory diseases, and cancer. | Biotech | Glasgow | Series B | $45.9M | 2026-08-05 | $90.6M | Scottish Enterprise, Sofinnova Partners, European Investment Fund +1 | 11 to 50 | 2014 |
| Alchemab Therapeutics | Alchemab Therapeutics develops protective antibodies to prevent hard-to-treat diseases. | Biotech | London | Series A | $33.6M | 2026-07-09 | $151.1M | DCVC, RA Capital Management, DHVC +2 | 51 to 100 | 2019 |
| Automata | Automata provides laboratory automation software and hardware to increase efficiency in scientific workflows. | Artificial intelligence | London | Series C | $45.0M | 2026-06-25 | $144.8M | Octopus Ventures, Firstminute Capital, Hummingbird Ventures +1 | 101 to 250 | 2015 |
| Apoha | Apoha is a start-up that has not yet publicly launched. | Biotech | London | Series A | $36.0M | 2026-06-03 | $36.0M | Plug and Play, Innovate UK, Intel Ignite +2 | 1 to 10 | 2021 |
| Imperagen | Imperagen is a biotechnology company that researches enzyme engineering, artificial intelligence, and synthetic biology. | Artificial intelligence | Manchester | Seed | $6.7M | 2026-05-20 | $11.0M | IQ Capital, Northern Gritstone | 11 to 50 | 2021 |
| CellCentric | CellCentric develops small molecule therapies for treating cancer and multiple myeloma. | Biotech | Cambridge | Series D | $220.0M | 2026-05-06 | $475.7M | Innovate UK, 5Y Capital, RA Capital Management +2 | 11 to 50 | 2003 |
| Fermtech | Fermtech provides equipment that helps precision fermentation companies scale production processes. | Biotech | Oxford | Seed | $3.3M | 2026-04-07 | $3.9M | Carbon13 | 1 to 10 | 2022 |
| Corryn Biotechnologies | Corryn Biotechnologies develops wound dressing devices for chronic and complex wounds. | Biotech | Morriston | Seed | $662K | 2026-04-01 | $1.6M | SFC Capital, Innovate UK | 1 to 10 | 2021 |
| Lucida Medical | Lucida Medical develops software for cancer diagnosis using MRI and radiology imaging, particularly for prostate cancer. | Biotech | Cambridge | Series A | $11.5M | 2026-03-30 | $22.5M | Innovate UK, XTX Ventures, WDH Investments | 11 to 50 | 2019 |
| Brainomix | Brainomix creates AI-powered imaging biomarkers that support precision medicine treatment decisions. | Artificial intelligence | Oxford | Series C | $6.5M | 2026-02-24 | $60.2M | Innovate UK, Parkwalk Advisors, Boehringer Ingelheim Venture Fund +1 | 51 to 100 | 2010 |
| sable bio | Sable Bio uses artificial intelligence to analyze large biomedical datasets and test drug candidates for toxicity. | Artificial intelligence | London | Seed | $3.8M | 2026-02-11 | $5.6M | Seedcamp, Episode 1 | 1 to 10 | 2023 |
| Early Health | Early Health makes consumer bathroom hardware that detects early signs of illness. | Biotech | London | Seed | $4.7M | 2026-02-10 | $4.7M | LocalGlobe, SoftBank Vision Fund, Atomico +1 | 1 to 10 | 2022 |
| KluraLabs | KluraLabs manufactures products that use nanotechnology to inactivate viruses and bacteria. | Biotech | Haverhill | Series A | $11.0M | 2026-02-03 | $11.0M | Starship Ventures | 11 to 50 | 2020 |
| Sparxell | Sparxell creates new colors and effects. | Biotech | Cambridge | Seed | $5.0M | 2026-02-03 | $10.2M | Katapult, Joyance Partners, Earth Venture Capital +1 | 11 to 50 | 2022 |
| Infinitopes | Infinitopes develops vaccines for the treatment of cancer. | Biotech | Oxford | Seed | $15.4M | 2026-01-21 | $31.4M | Octopus Ventures, Kindred Capital, Martlet Capital +1 | 11 to 50 | 2021 |
| Nuclera | Nuclera provides a protein prototyping system that makes proteins readily available to drug discovery researchers. | Biotech | Cambridge | Series C | $12.0M | 2026-01-13 | $157.8M | Innovate UK, Verve Ventures, Amadeus Capital Partners +2 | 101 to 250 | 2013 |
| EpilepsyGTx | EpilepsyGTx develops gene therapies to improve management of focal refractory epilepsy in late-stage clinical development. | Biotech | Canterbury | Series A | $33.0M | 2025-12-10 | $43.0M | UCL Technology Fund, HTH | 1 to 10 | 2021 |
| Emm | Emm develops bio-wearable devices intended to improve healthcare. | Biotech | London | Seed | $8.9M | 2025-11-19 | $9.9M | Alumni Ventures, Innovate UK, Sie Ventures | 11 to 50 | 2020 |
| InvenireX | InvenireX offers molecular diagnostics services as a biotechnology company. | Biotech | Newcastle Upon Tyne | Seed | $2.6M | 2025-11-18 | $3.3M | XTX Ventures, DSW Ventures | 1 to 10 | 2021 |
| OXCCU | OXCCU converts carbon dioxide and hydrogen into synthetic fuels, chemicals, and biodegradable plastics. | Biotech | Oxford | Series B | $27.9M | 2025-09-29 | $54.1M | IP Group, Aramco Ventures, Clean Energy Ventures +1 | 1 to 10 | 2021 |
| Cyted | Cyted uses AI and digital pathology to improve the detection and diagnosis of diseases, including cancer. | Artificial intelligence | Cambridge | Series B | $44.0M | 2025-08-30 | $83.4M | Innovate UK, MedTech Innovator, Morningside +1 | 51 to 100 | 2018 |
| Verdiva Bio | Verdiva Bio develops treatments for patients with obesity and cardiometabolic diseases. | Biotech | London | Series A | $411.0M | 2025-01-09 | $411.0M | General Atlantic, RA Capital Management, OrbiMed +1 | 11 to 50 | 2024 |
| OxCan | OxCan develops machine learning and liquid biopsy tools for early lung cancer detection. | Biotech | Oxford | Series A | $11.0M | 2025-01-09 | $16.4M | Civilization Ventures, Eka Ventures, Oxford Technology Management +1 | 11 to 50 | 2020 |
| Amped PCR | Amped PCR manufactures reagents and develops PurifAI. | Artificial intelligence | Cardiff | Seed | $679K | 2024-12-16 | SFC Capital | 1 to 10 | 2022 |
Table 1. Biotech startups in the United Kingdom: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 638.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CellCentric | CellCentric develops small molecule therapies for treating cancer and multiple myeloma. | Biotech | Cambridge | Series D | $220.0M | 2026-05-06 | $475.7M | Innovate UK, 5Y Capital, RA Capital Management +2 | 11 to 50 | 2003 |
| 2 | Basecamp Research | Basecamp Research is a biotechnology company that uses AI and biological data to develop therapeutics. | Artificial intelligence | London | Series C | $140.0M | 2026-09-23 | $219.9M | True Ventures, redalpine, Hummingbird Ventures +1 | 51 to 100 | 2019 |
| 3 | T-Therapeutics | T-Therapeutics develops T cell receptor therapies, spun off from the University of Cambridge. | Biotech | Cambridge | Series B | $133.0M | 2026-11-05 | $224.6M | F-Prime, Sofinnova Partners, Digitalis Ventures +2 | 51 to 100 | 2022 |
| 4 | Microbiotica | Microbiotica develops live bacterial microbiome therapeutics and associated biomarkers. | Biotech | Cambridge | Series C | $47.9M | 2026-10-16 | $130.7M | Seventure Partners, IP Group, Cambridge Innovation Capital +1 | 11 to 50 | 2016 |
| 5 | Mironid | Mironid discovers drugs to treat degenerative kidney diseases, chronic inflammatory diseases, and cancer. | Biotech | Glasgow | Series B | $45.9M | 2026-08-05 | $90.6M | Scottish Enterprise, Sofinnova Partners, European Investment Fund +1 | 11 to 50 | 2014 |
| 6 | Automata | Automata provides laboratory automation software and hardware to increase efficiency in scientific workflows. | Artificial intelligence | London | Series C | $45.0M | 2026-06-25 | $144.8M | Octopus Ventures, Firstminute Capital, Hummingbird Ventures +1 | 101 to 250 | 2015 |
| 7 | Sava Technology | Sava Technology creates under-skin sensors that continuously monitor glucose, lactate, and ketones. | Biotech | London | Series B | $36.0M | 2026-10-09 | $62.8M | SOSV, Balderton Capital, Social Starts +1 | 101 to 250 | 2016 |
| 8 | Apoha | Apoha is a start-up that has not yet publicly launched. | Biotech | London | Series A | $36.0M | 2026-06-03 | $36.0M | Plug and Play, Innovate UK, Intel Ignite +2 | 1 to 10 | 2021 |
| 9 | Alchemab Therapeutics | Alchemab Therapeutics develops protective antibodies to prevent hard-to-treat diseases. | Biotech | London | Series A | $33.6M | 2026-07-09 | $151.1M | DCVC, RA Capital Management, DHVC +2 | 51 to 100 | 2019 |
| 10 | EpilepsyGTx | EpilepsyGTx develops gene therapies to improve management of focal refractory epilepsy in late-stage clinical development. | Biotech | Canterbury | Series A | $33.0M | 2025-12-10 | $43.0M | UCL Technology Fund, HTH | 1 to 10 | 2021 |
Table 2. Biotech startups in the United Kingdom: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Innovate UK | Entrepreneurship program | Swindon, United Kingdom | 30 | 5% | 8 | Bioliberty, Apoha, CellCentric |
| 2 | SFC Capital | Angel group | Northwich, United Kingdom | 11 | 2% | 1 | Corryn Biotechnologies |
| 3 | Scottish Enterprise | Government investment office | Glasgow, United Kingdom | 10 | 2% | 2 | Bioliberty, Mironid |
| 4 | Octopus Ventures | Venture capital firm | London, United Kingdom | 10 | 2% | 2 | Automata, Infinitopes |
| 5 | Future Planet Capital | Venture capital firm | London, United Kingdom | 9 | 1% | 2 | CellCentric, Nuclera |
| 6 | Oxford Science Enterprises | Venture capital firm | Oxford, United Kingdom | 8 | 1% | ||
| 7 | SOSV | Venture capital firm | Princeton, United States | 6 | 1% | 1 | Sava Technology |
| 8 | Techstars | Startup accelerator | New York, United States | 6 | 1% | ||
| 9 | Sofinnova Partners | Venture capital firm | Paris, France | 5 | 1% | 2 | T-Therapeutics, Mironid |
| 10 | Eos | Venture capital firm | Saint Andrews, United Kingdom | 5 | 1% | 1 | Bioliberty |
| 11 | Parkwalk Advisors | Venture capital firm | London, United Kingdom | 4 | 1% | 1 | Brainomix |
| 12 | IP Group | Venture capital firm | London, United Kingdom | 4 | 1% | 1 | Microbiotica |
| 13 | Old College Capital | University program | Edinburgh, United Kingdom | 4 | 1% | 1 | Bioliberty |
| 14 | IQ Capital | Venture capital firm | London, United Kingdom | 4 | 1% | 1 | Imperagen |
| 15 | Verve Ventures | Venture capital firm | Zug, Switzerland | 4 | 1% | 1 | Nuclera |
Table 3. Biotech startups in the United Kingdom: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 457 | 72% | $9.5B |
| Software | 132 | 21% | $1.2B |
| Artificial intelligence | 86 | 13% | $888.1M |
| Hardware | 27 | 4% | $370.4M |
| Fintech | 16 | 3% | $15.5M |
| Cybersecurity | 10 | 2% | $26.5M |
| Education | 7 | 1% | $284.5M |
| Energy | 5 | 1% | $56.9M |
| Commerce | 1 | 0% | $11.0M |
Table 4. Biotech startups in the United Kingdom by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Biotech startups in the United Kingdom by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| London | 242 | 38% |
| Cambridge | 85 | 13% |
| Oxford | 47 | 7% |
| Edinburgh | 22 | 3% |
| Manchester | 20 | 3% |
| Bristol | 15 | 2% |
| Glasgow | 12 | 2% |
| Stevenage | 10 | 2% |
| Newcastle Upon Tyne | 9 | 1% |
| Reading | 8 | 1% |
| Nottingham | 7 | 1% |
| Cardiff | 6 | 1% |
Table 6. Biotech startups in the United Kingdom by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 6 | 7% | $253.3M |
| October 2026 | 11 | 12% | $439.4M |
| September 2026 | 10 | 11% | $157.3M |
| August 2026 | 3 | 3% | $48.3M |
| July 2026 | 6 | 7% | $130.4M |
| June 2026 | 8 | 9% | $321.1M |
| May 2026 | 11 | 12% | $339.3M |
| April 2026 | 6 | 7% | $78.5M |
| March 2026 | 8 | 9% | $232.3M |
| February 2026 | 8 | 9% | $56.6M |
| January 2026 | 5 | 6% | $62.8M |
| December 2025 | 3 | 3% | $36.5M |
| November 2025 | 5 | 6% | $145.1M |
Table 7. Biotech startups in the United Kingdom: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 82 | 13% | $2.1B |
| 2025 | 64 | 10% | $1.3B |
| 2024 | 92 | 14% | $1.4B |
| 2023 | 73 | 11% | $663.4M |
| 2022 | 57 | 9% | $675.3M |
| 2021 | 55 | 9% | $1.0B |
Table 8. Biotech startups in the United Kingdom by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 72 | 11% |
| 2020 to 2022 | 161 | 25% |
| 2015 to 2019 | 224 | 35% |
| 2010 to 2014 | 100 | 16% |
| Before 2010 | 75 | 12% |
Table 9. Biotech startups in the United Kingdom by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 298 | 48% |
| 11 to 50 | 267 | 43% |
| 51 to 100 | 38 | 6% |
| 101 to 250 | 19 | 3% |
| 251 to 500 | 3 | 0% |
| 1,001 to 5,000 | 1 | 0% |
Table 10. Biotech startups in the United Kingdom by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its headquarters is in the United Kingdom. On 16 November 2026 that is 638 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 638 rows: 142 have no round amount, 1 no city and 242 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in the United Kingdom are on the list?
- 638, in the file dated 16 November 2026. 90 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 638 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $349.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.